一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (467k)
Article in Japanese

Case Report

Antitumor activity of alectinib against central nervous system metastases in patients with crizotinib-resistant ALK-positive lung cancer

Keigo Kobayashia  Nasa Morokawaa  Kyoko Murasea  Shigeo Hanadaa  Hisashi Takayaa  Kazuma Kishia,b 

aDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital
bOkinaka Memorial Institute for Medical Research

ABSTRACT

Although crizotinib shows marked and durable activity in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), the central nervous system (CNS) is a frequent site of disease progression in such patients. Alectinib, one of the second-generation ALK inhibitors, is a novel, highly potent, and selective ALK inhibitor that has demonstrated promising antitumor activity in CNS metastases. In this report, we present a series of four ALK-positive NSCLC patients who developed metastatic lesions in CNS, such as brain, leptomeninges, and spinal cord, during crizotinib treatment. All patients subsequently received alectinib, resulting in clinical response without serious side effects. Alectinib was effective for the treatment of CNS metastases in crizotinib-resistant ALK-positive NSCLC patients.

KEYWORDS

ALK-rearranged non-small cell lung cancer  Spinal cord metastasis  Meningeal carcinomatosis  Crizotinib  Alectinib 

Received 29 Sep 2015 / Accepted 2 Mar 2016

AJRS, 5(4): 184-188, 2016

Google Scholar